Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 364,615 shares were traded during trading, an increase of 109% from the previous session's volume of 174,150 shares.The stock last traded at $20.55 and had previously closed at $20.65.
Analyst Ratings Changes
Several research firms recently commented on GRDN. Truist Financial reaffirmed a "buy" rating and set a $28.00 price objective (up from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th. Raymond James set a $28.00 target price on Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. Finally, Wall Street Zen cut shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th.
Read Our Latest Report on Guardian Pharmacy Services
Guardian Pharmacy Services Stock Performance
The firm has a 50 day moving average of $23.12 and a 200-day moving average of $21.93.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). The business had revenue of $329.31 million during the quarter, compared to analyst estimates of $321.21 million. On average, equities analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current fiscal year.
Insider Transactions at Guardian Pharmacy Services
In other Guardian Pharmacy Services news, Director William E. Bindley sold 651,454 shares of the company's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $20.16, for a total value of $13,133,312.64. Following the transaction, the director now owns 1,939,817 shares of the company's stock, valued at $39,106,710.72. This represents a 25.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Kendall Forbes sold 64,991 shares of the company's stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $1,310,218.56. Following the completion of the transaction, the insider now directly owns 203,906 shares in the company, valued at $4,110,744.96. This trade represents a 24.17% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,344,912 shares of company stock worth $228,713,426. 63.71% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Guardian Pharmacy Services
Hedge funds and other institutional investors have recently made changes to their positions in the company. Nuveen Asset Management LLC grew its position in shares of Guardian Pharmacy Services by 2.9% during the 4th quarter. Nuveen Asset Management LLC now owns 547,140 shares of the company's stock worth $11,085,000 after buying an additional 15,550 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Guardian Pharmacy Services during the fourth quarter valued at about $544,000. Rhumbline Advisers bought a new stake in Guardian Pharmacy Services during the fourth quarter valued at about $149,000. Northern Trust Corp bought a new stake in Guardian Pharmacy Services during the fourth quarter valued at about $1,479,000. Finally, New York State Common Retirement Fund boosted its position in Guardian Pharmacy Services by 17.9% during the fourth quarter. New York State Common Retirement Fund now owns 278,548 shares of the company's stock valued at $5,643,000 after purchasing an additional 42,368 shares in the last quarter.
Guardian Pharmacy Services Company Profile
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
See Also
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
